Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant high blood pressure, today announces the signing of an agreement exclusive licensing and collaboration with Xediton Pharmaceuticals to develop and commercialize firibastat in Canada.

Under the terms of the agreement, Xediton Pharmaceuticals will receive the exclusive rights to market firibastat for the treatment of difficult-to-treat / resistant hypertension in Canada. Quantum Genomics has also recruited its first patients in Canada as part of the phase III FRESH study.

Quantum Genomics will receive upfront and milestone payments of up to $ 11.35 million as well as double-digit royalties on future sales of the firibastat.

The population suffering from difficult-to-treat and resistant arterial hypertension for the territories mentioned is estimated between 1 and 1.5 million.

'We are delighted with this new agreement with Xediton Pharmaceuticals, a private specialty pharmaceutical company. We share common values: to have a positive impact on the lives of our patients through our products and our physicians. With an experienced management team, Xediton Pharmaceuticals is a fully operational company that already has three drugs in the cardiovascular market, 'said Jean-Philippe Milon, CEO of Quantum Genomics.

'We are very happy to partner with Quantum Genomics to bring firibastat to Canadian patients. Although many treatments for high blood pressure are available, there is no alternative for patients with difficult to treat hypertension. and resitante. We look forward to the placing on the market firibastat because it will be extremely beneficial for patients with difficult to treat hypertension / resistant 'said George Gafrey, president of XEDITON Pharmaceuticals Inc.

About Xediton Pharmaceuticals

Xediton Pharmaceuticals is a privately held pharmaceutical company dedicated to meeting the needs of patients, physicians and healthcare partners or professionals. Xediton Pharmaceuticals is committed to developing, partnering and making available new and existing drugs to improve the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals offers products in the areas of oncology, anti-infective, pain, digestive, ophthalmology and heart failure. It has forged solid strategic alliances with internationally renowned pharmaceutical companies.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of cerebral Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it is based on more than twenty years of research work from the University of Paris-Descartes and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or have failed treatment), and

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the American market OTCQX (symbol: QNNTF).

Contact:

Nathalie Boumendil

Tel: 06 85 82 41 95

Email: nathalie@so-bang.fr

(C) 2020 Electronic News Publishing, source ENP Newswire